New study findings suggest that an epigenetic test could be created to identify those individuals early in the process of developing diabetes mellitus, providing hope for preventing the disease.
Four functional genes with roles in insulin resistance have now been detected by an experimental epigenetic analysis of obesity. These study findings suggest that an epigenetic test could be created to identify those individuals early in the process of developing diabetes mellitus, providing hope for preventing the disease.
Andrew P. Feinberg, MD, and coworkers from Johns Hopkins University School of Medicine undertook a comparison of cells from mice that were overfed to mice that were lean to determine obesity-associated changes in epigenetic chemical tags on DNA. These chemical tags affect if and how much genes are used without actually changing the genetic code.
Mice were fed either a normal diet or a high-calorie diet; mice on the high-calorie diet became obese and diabetic. Clear differences were observed between the obese and normal mice through analysis of epigenetic markers at more than 7 million sites in the DNA of their fat cells. Some sites with chemical tags called methyl groups were found in the lean mice but were missing in the obese mice, and vice versa. Methyl groups prevent genes from making proteins, which are needed for insulin secretion and proper metabolism.
Researchers extended the analysis to humans, using adipose samples from lean and obese patients before and after gastric bypass surgery. The same pattern of differences was found.
As Feinberg comments, “Mice and humans are separated by 50 million years of evolution, so it’s interesting that obesity causes similar epigenetic changes to similar genes in both species.” He adds, “It’s likely that when food supplies are highly variable, these epigenetic changes help our bodies adapt to temporary surges in calories. But if the high-calorie diet continues over the long term, the same epigenetic pattern raises the risk for disease.”
Some of the epigenetic changes associated with obesity affected genes known to elevate diabetes risk. Other epigenetic changes affected genes not definitively linked to diabetes, but connected to metabolism-how the body breaks down and uses nutrients. Further tests showed that some of these genes regulate insulin action on sugar uptake.
These research results point the way forward in diabetes research with regard to new potential drug targets for treating type 2 diabetes.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More